Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents

Biochem Soc Trans. 2004 Dec;32(Pt 6):959-61. doi: 10.1042/BST0320959.


PARP [poly(ADP-ribose) polymerase] activity is up-regulated by binding to DNA strand breaks and its association with DNA repair is well documented. Many anticancer therapies work by inducing breaks in DNA, if unrepaired these can lead to cell death. As PARP promotes DNA repair there is a strong rational to suggest that its inhibition may increase the efficiency of certain cytotoxic treatments. This review discusses the advances made in PARP inhibitor design and the mechanism by which they enhance anti-tumour therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Azulenes
  • Benzodiazepines / pharmacology
  • DNA Replication / drug effects
  • Drug Design
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Poly(ADP-ribose) Polymerase Inhibitors*


  • 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one
  • Antineoplastic Agents
  • Azulenes
  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Benzodiazepines